PortfoliosLab logo
Exact Sciences Corporation (EXAS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US30063P1057

CUSIP

30063P105

IPO Date

Feb 1, 2001

Highlights

Market Cap

$10.64B

EPS (TTM)

-$5.55

PEG Ratio

-1.07

Total Revenue (TTM)

$2.83B

Gross Profit (TTM)

$1.93B

EBITDA (TTM)

-$848.74M

Year Range

$39.97 - $72.83

Target Price

$68.83

Short %

6.13%

Short Ratio

3.72

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Exact Sciences Corporation (EXAS) returned 0.41% year-to-date (YTD) and 11.99% over the past 12 months. Over the past 10 years, EXAS returned 7.84% annually, underperforming the S&P 500 benchmark at 10.89%.


EXAS

YTD

0.41%

1M

35.69%

6M

14.37%

1Y

11.99%

5Y*

-7.63%

10Y*

7.84%

^GSPC (Benchmark)

YTD

1.30%

1M

12.79%

6M

1.49%

1Y

12.35%

5Y*

15.12%

10Y*

10.89%

*Annualized

Monthly Returns

The table below presents the monthly returns of EXAS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-0.25%-15.41%-8.69%5.43%23.62%0.41%
2024-11.60%-12.03%20.04%-14.06%-23.42%-7.04%8.12%35.05%10.42%1.19%-9.94%-9.49%-24.05%
202336.38%-7.69%8.79%-5.52%27.33%15.10%3.88%-14.22%-18.47%-9.72%3.91%15.59%49.42%
2022-1.89%2.23%-10.43%-21.27%-9.52%-20.92%14.50%-21.18%-8.61%7.05%29.24%10.14%-36.39%
20213.52%-0.76%-3.19%0.03%-16.15%12.47%-13.25%-3.21%-8.56%-0.24%-10.34%-8.83%-41.26%
20200.87%-13.22%-28.35%36.17%8.74%1.23%8.98%-20.54%35.41%21.46%-2.24%9.44%43.26%
201942.76%1.02%-4.81%13.93%5.01%13.91%-2.48%3.57%-24.20%-3.73%-6.89%14.16%46.56%
2018-5.39%-10.26%-9.59%24.00%19.06%0.42%-2.24%28.13%5.38%-9.97%9.75%-19.08%20.10%
201741.84%13.56%9.76%27.05%21.53%-3.02%9.70%7.96%12.49%16.70%8.17%-11.67%293.26%
2016-28.82%-23.44%34.00%4.15%-5.41%84.49%41.88%6.27%0.54%-16.10%-5.20%-9.55%44.75%
2015-0.84%-17.42%-2.00%-5.09%29.23%10.11%-19.07%-8.14%-18.63%-53.70%9.12%1.54%-66.36%
201410.64%3.46%5.35%-15.31%12.33%26.34%-8.34%33.57%-7.05%24.20%3.12%10.56%133.53%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of EXAS is 54, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of EXAS is 5454
Overall Rank
The Sharpe Ratio Rank of EXAS is 5858
Sharpe Ratio Rank
The Sortino Ratio Rank of EXAS is 5353
Sortino Ratio Rank
The Omega Ratio Rank of EXAS is 5353
Omega Ratio Rank
The Calmar Ratio Rank of EXAS is 5454
Calmar Ratio Rank
The Martin Ratio Rank of EXAS is 5353
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Exact Sciences Corporation (EXAS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Exact Sciences Corporation Sharpe ratios as of May 18, 2025 (values are recalculated daily):

  • 1-Year: 0.15
  • 5-Year: -0.14
  • 10-Year: 0.13
  • All Time: 0.08

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Exact Sciences Corporation compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Exact Sciences Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Exact Sciences Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Exact Sciences Corporation was 98.01%, occurring on Nov 24, 2008. Recovery took 1437 trading sessions.

The current Exact Sciences Corporation drawdown is 63.60%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.01%Sep 11, 20031312Nov 24, 20081437Aug 13, 20142749
-84.15%Jun 25, 2015172Mar 1, 2016294May 1, 2017466
-80.42%Feb 16, 2021421Oct 14, 2022
-69.06%Sep 6, 2019134Mar 18, 2020155Oct 27, 2020289
-64.67%Feb 2, 200146Apr 9, 200161Jul 6, 2001107

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Exact Sciences Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Exact Sciences Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 23.8% positive surprise.


-2.50-2.00-1.50-1.00-0.500.0020212022202320242025
-0.36
-0.47
Actual
Estimate

Valuation

The Valuation section provides an overview of how Exact Sciences Corporation is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for EXAS compared to other companies in the Diagnostics & Research industry. EXAS currently has a PEG ratio of -1.1. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for EXAS relative to other companies in the Diagnostics & Research industry. Currently, EXAS has a P/S ratio of 3.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for EXAS in comparison with other companies in the Diagnostics & Research industry. Currently, EXAS has a P/B value of 4.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items